Genomic Profiling with MammaPrint + BluePrint Predicts Anthracycline Chemotherapy Benefit and Guides Personalized Treatment Selection in HR+HER2- Early-Stage Breast Cancer
FLEX Study data shows that patients with MammaPrint High Read More
FLEX Study data shows that patients with MammaPrint High Read More
Additional research highlights integration of BluePrint molecular subtyping and Read More
Multivariate analyses reveal that pathologic complete response is associated Read More
Poster presentations highlight the prognostic value of MammaPrint + Read More
Multicenter study of over 1000 females with breast cancer, Read More
Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Read More
Four additional poster presentations from the ongoing real-world FLEX Read More
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – August 12, Read More
FLEX Study Highlights Clinical Utility of MammaPrint® and BluePrint® Read More
FLEX Study reaches milestone of 20,000 enrolled patients, providing Read More